Teachers Advisors LLC boosted its holdings in Diplomat Pharmacy (NYSE:DPLO) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,999 shares of the company’s stock after acquiring an additional 2,541 shares during the quarter. Teachers Advisors LLC’s holdings in Diplomat Pharmacy were worth $5,981,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in Diplomat Pharmacy in the fourth quarter valued at $773,000. Stone Ridge Asset Management LLC acquired a new stake in Diplomat Pharmacy in the fourth quarter valued at $1,136,000. Deutsche Bank AG grew its holdings in Diplomat Pharmacy by 7.6% in the fourth quarter. Deutsche Bank AG now owns 395,832 shares of the company’s stock valued at $7,943,000 after purchasing an additional 28,089 shares during the last quarter. Tekla Capital Management LLC grew its holdings in Diplomat Pharmacy by 38.7% in the fourth quarter. Tekla Capital Management LLC now owns 640,492 shares of the company’s stock valued at $12,855,000 after purchasing an additional 178,780 shares during the last quarter. Finally, Fred Alger Management Inc. grew its holdings in Diplomat Pharmacy by 1.2% in the fourth quarter. Fred Alger Management Inc. now owns 610,405 shares of the company’s stock valued at $12,251,000 after purchasing an additional 7,193 shares during the last quarter. Hedge funds and other institutional investors own 64.64% of the company’s stock.
In related news, Director Philip R. Hagerman sold 2,150,000 shares of the stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $20.65, for a total transaction of $44,397,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 30.20% of the stock is owned by company insiders.
Several analysts have weighed in on DPLO shares. Deutsche Bank raised Diplomat Pharmacy from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Needham & Company LLC set a $28.00 target price on Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, February 27th. Leerink Swann set a $30.00 target price on Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, February 27th. Lake Street Capital started coverage on Diplomat Pharmacy in a report on Friday, February 9th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Mizuho set a $25.00 target price on Diplomat Pharmacy and gave the company a “hold” rating in a report on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Diplomat Pharmacy currently has a consensus rating of “Hold” and an average target price of $25.38.
DPLO opened at $19.72 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1,460.64, a P/E ratio of 22.67 and a beta of 1.32. Diplomat Pharmacy has a 52 week low of $14.00 and a 52 week high of $27.78.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.02. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 earnings per share. equities analysts predict that Diplomat Pharmacy will post 0.94 earnings per share for the current fiscal year.
WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/diplomat-pharmacy-dplo-shares-bought-by-teachers-advisors-llc.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.